PT  - JOURNAL ARTICLE
AU  - Yan Liu
AU  - Christopher Bailey
AU  - Christopher Lazarski
AU  - Chun-shu Wong
AU  - Pan Zheng
AU  - Yang Liu
AU  - Yin Wang
TI  - Treatment of Graft-versus-Host Disease by Echinomycin in a New Humanized Mouse Model
AID  - 10.1101/108951
DP  - 2017 Jan 01
TA  - bioRxiv
PG  - 108951
4099  - http://biorxiv.org/content/early/2017/02/16/108951.short
4100  - http://biorxiv.org/content/early/2017/02/16/108951.full
AB  - Drug development effort against GVHD is hampered by the lack of clinically relevant humanized animal models for preclinical testing. Current humanized GVHD models rely on adoptive transfer of a high number of human peripheral blood mononuclear cells (PBMCs) into immunodeficient mice. Here we report a novel humanized GVHD model by transplanting a small number of human BM cells into newborn NOD. SCID IL2ry0 (NSG) mice. Transplantation of human BM cells (BMT) causes acute GVHD, with lethality between 15 to 60 days. Pervasive human T-cell infiltration into multiple organs, including lung, intestine, skin, kidney, liver, and stomach, was observed in all mice analyzed. Surprisingly, the human T cells express high levels of hypoxia inducible factor 1α (HIF1α) protein even under normoxic environment. Administration of Echinomycin, a potent inhibitor for HIF1α, rapidly ablated HIF1α protein in T cells and gradually reduced the frequency of human cells in the peripheral blood and target organs. Echinomycin provides a sustained therapeutic effect, as demonstrated by dramatic reduction of clinical symptoms, pathology score and by doubling of the median life span of the chimeric mice. Our results reveal a critical role of HIF1α in GVHD and demonstrate that HIF1α inhibitors such as Echinomycin should be explored for clinical drug development against GVHD.